Aim­ing to brush last year's flop aside, Ful­crum sees shares sky­rock­et on ear­ly look at sick­le cell pro­gram

Ful­crum Ther­a­peu­tics $FULC is look­ing to re­bound af­ter the Phase II flop of an old Glax­o­SmithK­line drug slashed their mar­ket val­ue in half last Au­gust. And if Tues­day’s stock move­ment is any in­di­ca­tion, in­vestors like what they see.

At an in­ter­im analy­sis of a Phase I study, Ful­crum re­port­ed that their pro­gram de­signed to treat in­her­it­ed blood dis­or­ders hit a sta­tis­ti­cal­ly sig­nif­i­cant rate in two key mea­sure­ments, the com­pa­ny an­nounced Tues­day morn­ing. The re­sults sent Ful­crum shares sky­rock­et­ing more than 125%, send­ing the stock price back above what it had been be­fore last year’s whiff.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER